Vimarsana
Biggest News Aggregation in the World

Page 6 - Compugen Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Compugen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Compugen Ltd Today - Breaking & Trending Today

Gilead Sciences, Inc. and Compugen Ltd. Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program - Vimarsana News

Gilead Sciences, Inc. and Compugen Ltd. Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Gilead Sciences Inc. announced an agreement with Compugen Ltd. to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503...

Gilead Sciences, Compugen Sign Exclusive Licensing Deal for Pre-Clinical Immunotherapy Program; Compugen Shares Soar - Vimarsana News

Gilead Sciences, Compugen Sign Exclusive Licensing Deal for Pre-Clinical Immunotherapy Program; Compugen Shares Soar

-- Gilead Sciences said Tuesday that it has signed an agreement with Compugen Ltd. to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein,...

Related Topics:
Compugen Ltd
Compugen's stock rockets on deal with Gilead for anti-tumor drug - Vimarsana News

Compugen's stock rockets on deal with Gilead for anti-tumor drug

Shares are halted for volatility but rise to highest levels since mid-2022 on resumed trading.

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - BYND Cannasoft Enterprise (NASDAQ:BCAN), Affirm Holdings (NASDAQ:AFRM) - Vimarsana News

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - BYND Cannasoft Enterprise (NASDAQ:BCAN), Affirm Holdings (NASDAQ:AFRM)

Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program. Compugen shares jumped 204.1% to $2.22 on Tuesday.

Compugen (NASDAQ:CGEN) Price Target Raised to $4.00 - Vimarsana News

Compugen (NASDAQ:CGEN) Price Target Raised to $4.00

Compugen (NASDAQ:CGEN – Get Free Report) had its target price raised by investment analysts at Stifel Nicolaus from $3.00 to $4.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target suggests a potential upside of […]